Full Press Release Details
Eloxx Pharmaceuticals Adds Additional Treatment
Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Fifth Treatment Arm to Evaluate Safety of ELX-02
in Combination with Kalydeco (ivacaftor)
Reaffirmed Data Readout for First Four Treatment
Arms On Track for Second Half of 2021
WALTHAM, MA - APRIL 29, 2021 - Eloxx Pharmaceuticals,
Inc. (NASDAQ: ELOX) today announced the addition of a new study arm in the ongoing global Phase 2 clinical program for ELX-02 for the
treatment of cystic fibrosis (CF) in patients with at least one G542X allele. The Phase 2 clinical program now includes a fifth treatment
arm to evaluate safety of ELX-02 in combination with Kalydeco (ivacaftor), an FDA-approved CFTR (CF transmembrane conductance regulator)
potentiator for the treatment of cystic fibrosis in patients who have at least one mutation in their CF gene amenable to ivacaftor. The
Phase 2 trials are designed to evaluate the safety of ELX-02 and assess its biological activity.
"We are extremely pleased to include this additional treatment
arm in the ongoing Phase 2 clinical trial to further explore the potential of ELX-02 to treat cystic fibrosis," said Sumit Aggarwal,
President and Chief Executive Officer. "Given ELX-02's potential to treat CFTR nonsense mutations and the synergistic effects
of ELX-02 and ivacaftor seen to date in pre-clinical models, we believe that combination treatment with a CFTR potentiator, such as ivacaftor,
provides the opportunity to improve clinical efficacy in the treatment of CF. We remain on track to present data from the first four treatment
arms of the study in the second half of this year."
ELX-02 is currently in Phase 2 clinical trials in CF patients affected
by nonsense mutations in the CFTR gene. The trial currently has sites in the U.S., Europe, Israel, Australia and Canada. Several planned
Safety Review Committee meetings have occurred and allowed dose escalation up to the top dose level, and data have shown no drug-related
serious adverse events reported to date. Multiple patients have progressed through the four-dose escalation treatment range. The program
is partially funded by the Cystic Fibrosis Foundation (CFF). The U.S. Food and Drug Administration has granted orphan drug designation
for ELX-02 for the treatment of CF.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome
modulation, leveraging both its innovative TURBO-ZMTM chemistry technology platform in an effort to develop novel Ribosome
Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx's lead investigational product
candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in
clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory
body. Eloxx also has preclinical programs focused on select rare diseases including inherited diseases, cancer caused by nonsense mutations,
kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.
For more information, please visit www.eloxxpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts
contained in this press release, including without limitation, statements regarding the expected timing of trials and results from clinical
studies of our product candidate, the expansion of our clinical trial sites and the potential of our product candidate to treat nonsense
mutations are forward-looking statements. Forward-looking statements can be identified by the words "aim," "may,"
"will," "would," "should," "expect," "explore," "plan," "anticipate,"
"could," "intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential," "seeks," or "continue" or the negative
of these terms similar expressions, although not all forward-looking statements contain these words.
Forward-looking statements are based on management's current
plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject
to known and unknown risks,uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed
or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to
progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that
positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of
our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment
from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors,
suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting,
defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future
through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory
environment, competition and market for our products; and business ability and judgment of personnel, and the availability of
qualified personnel and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form
10-K for the fiscal year ended December 31, 2020, as any such factors may be updated from time to time in our other filings with the
SEC, accessible on the SEC's website at www.sec.gov and the "Financials & Filings" page of our website
All forward-looking statements speak only as of the date of this
press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events, changed circumstances or otherwise.